BioAge Labs, Inc. (BIOA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 24, 2026, announces the financial results for BioAge Labs, Inc. for the fiscal year ended December 31, 2025. The Company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol BIOA. It is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period. It serves as a notification that the annual results have been issued and directs investors to the attached press release for specific performance data.
Guidance, Outlook, and Management Commentary
Management has updated the corporate deck, which is available on the Company's investor relations website. The filing includes standard Regulation FD disclosures and notes that the information in the press release and corporate deck is not deemed "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific revenue and net income figures for the year ended December 31, 2025, in the attached Exhibit 99.1 press release.
- Review the updated corporate deck on the investor relations website for forward-looking guidance and strategic updates.
- Confirm the Company's status as an emerging growth company and any associated accounting standard elections.
- Note that the financial data in this 8-K is not incorporated by reference into other SEC filings.